John Chorba, MD

Assistant Professor

Dr. John Chorba is a physician-scientist at UCSF and a general, non-invasive cardiologist at the Zuckerberg San Francisco General Hospital. He is trained a chemical biologist and uses chemical tools to probe the biological mechanisms of cardiovascular disease. His ultimate focus is on developing novel therapeutics and developing methods to “drug the undruggable.” He complements his basic investigations with clinical studies and teaching.

Dr. Chorba earned his bachelor’s degree in chemistry at Harvard College and his medical degree from Harvard Medical School. He completed internal medicine residency at the Massachusetts General Hospital and his cardiovascular fellowship at UCSF. He has done his postdoctoral research training with Kevan Shokat at UCSF. He has been an Assistant Professor in the Division of Cardiology at the Zuckerberg San Francisco General Hospital since 2014.
Education
Cardiology Fellowship, 2014 - , University of California, San Francisco
Internal Medicine Residency, 2010 - , Massachusetts General Hospital
M.D., 2007 - , Harvard Medical School
Honors and Awards
  • K08 Mentored Clinical Scientist Development Award, NIH/NHLBI, 2015-2020
  • ASPIRE Cardiovascular Award, Pfizer, 2015-2018
  • Hellman Fellowship, Hellman Fellows Fund, 2015-2017
  • Pilot Investigator Award, UCSF Academic Senate, 2015-2017
  • Catalyst Award, UCSF CTSI, 2015-2016
  • Loan Repayment Program, NIH/NHLBI, 2013-2017
  • Research Scholar in Cardiovascular Disease Award, Gilead Sciences, 2013-2016
  • Ruth L. Kirschstein F32 National Research Service Award, NIH/NHLBI, 2012-2014
  • Laennec Young Clinician Award, American Heart Association, 2011
Publications
  1. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
  2. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.
  3. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
  4. A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.
  5. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
  6. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
  7. An Educational and Administrative Intervention to Promote Rational Laboratory Test Ordering on an Academic General Medicine Service.
  8. The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.
  9. Brain natriuretic peptide predicts functional outcome in ischemic stroke.
  10. Sustained ventricular fibrillation in a conscious patient.
  11. Vesicular stomatitis viruses resistant to the methylase inhibitor sinefungin upregulate RNA synthesis and reveal mutations that affect mRNA cap methylation.
  12. Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series.
  13. Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues.